🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Mirati Therapeutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK, China, Ireland and India registers with Mirati Therapeutics as lead sponsor. Synced 26 Sep 2026
9Current trials
4Recruiting now
16Drugs in these trials
5Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Mirati Therapeutics is the lead sponsor of 9 current clinical trials in our USA, UK, China, Ireland and India registers. 4 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Adagrasib, Pembrolizumab and Cetuximab. The most-studied condition is Advanced Cancer.

ClinicalTrials.gov trials by status

  • Recruiting444%
  • Active, closed556%

Trials by phase

  • Phase 3333%
  • Phase 2333%
  • Phase 2/3111%
  • Phase 1111%
  • Phase 1/2111%
01

Clinical trials sponsored by Mirati Therapeutics

9 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent
NCT07723118 · Healthy Participants
Drug: Adagrasib
Phase 1 Recruiting 2026-08 USA
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310 · Carcinoma, Non-Small-Cell Lung
Phase 3 Recruiting 2025-04 Ireland, UK, USA, India, China
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Phase 2/3 Recruiting 2020-12 Ireland, UK, USA, India, China
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031 · Solid Tumors
Phase 2 Recruiting 2026-05 UK, USA, China
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249 · Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Phase 1/2 Active, closed 2019-01 USA
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Phase 3 Active, closed 2021-06 Ireland, UK, USA, China
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135 · ClinicalTrials.gov ↗ · Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Phase 3 Active, closed 2021-02 Ireland, UK, USA, China
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575 · ClinicalTrials.gov ↗ · Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
Drug: Adagrasib
Phase 2 Active, closed 2024-02 USA
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578 · ClinicalTrials.gov ↗ · Advanced NSCLC, Metastatic Lung Cancer
Drug: Adagrasib
Phase 2 Active, closed 2022-11 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Mirati Therapeutics trials

16 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Mirati Therapeutics trials

15 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA94
Clinical trials in UK53
Clinical trials in China53
Clinical trials in Ireland42
Clinical trials in India22

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Cancer

SponsorTrials
Chia Tai Tianqing Pharmaceutical Group3
Arcus Biosciences2
Transcenta Therapeutics (Hangzhou)2
Agenus1
MacroGenics1
Solve Therapeutics1
Biocity Biopharmaceutics1
HC Biopharma1

Sponsors with the most current trials registered for this condition.

06

Questions about Mirati Therapeutics trials

How many clinical trials does Mirati Therapeutics sponsor?

Mirati Therapeutics is the lead sponsor of 9 current trials on ClinicalTrials.gov in our USA, UK, China, Ireland and India registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Mirati Therapeutics trials recruiting?

Yes. 4 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Mirati Therapeutics testing?

Its current trials name 16 drugs and biologicals as interventions. The most frequent are Adagrasib (6), Pembrolizumab (4), Cetuximab (3), MRTX849 (3) and Docetaxel (2). The number in brackets is how many of its trials name each drug.

Does Mirati Therapeutics have clinical trials in Ireland?

Yes. 4 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.